Revium Rx. (RVRC)

Market Cap	101.42M +276,054.1%
Revenue (ttm)	n/a
Net Income	-13.45M
EPS	-0.22
Shares Out	60.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	262
Open	1.670
Previous Close	1.670
Day's Range	1.670 - 1.670
52-Week Range	0.520 - 1.670
Beta	-0.61
RSI	48.63
Earnings Date	n/a

About Revium Rx.

Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States. The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors. The company specializes in infectious diseases, including antibiotic-resistant infections, solid tumors and vaccination. The company also develops nano-liposomal particles (NLP) based pharmaceutical candidates. It develops nanoparticles-based formulation of a potent antibiotic; no...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 1997
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: RVRC